Daily Chart: AbbVie’s deals by disease and type

In the seven years since its split from Abbott, AbbVie has entered at least 38 disclosed therapeutics deals, including 20 in cancer.

Within cancer, AbbVie has engaged in about twice as many licensing and acquisition deals as research collaborations. The opposite trend is seen in neurology and autoimmune diseases, which rank second and third for most deals by the pharma. ...